Nightstar Therapeutics to Present at Chardan Genetic Medicines Conference
October 04 2018 - 6:05AM
Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene
therapy company developing treatments for rare inherited retinal
diseases, today announced that the company plans on presenting at
the Chardan Genetic Medicines Conference, on Tuesday October 9,
2018 at 2:45 p.m. ET in New York City.
To access the live webcast, please visit ir.nightstartx.com. A
replay of the webcast will be available on the Nightstar website
for two weeks following the conference.
About NightstarNightstar is a leading
clinical-stage gene therapy company focused on developing and
commercializing novel one-time treatments for patients suffering
from rare inherited retinal diseases that would otherwise progress
to blindness. Nightstar’s lead product candidate, NSR-REP1, is
currently in Phase 3 development for the treatment of patients with
choroideremia, a rare, degenerative, genetic retinal disorder that
has no current treatments. Results from a Phase 1/2 trial of
NSR-REP1 were published in The Lancet in 2014 and in The New
England Journal of Medicine in 2016. Nightstar’s second product
candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2
clinical trial for the treatment of patients with X-linked
retinitis pigmentosa, an inherited X-linked recessive retinal
disease.
For more information about Nightstar or its clinical trials,
please visit www.nightstartx.com.
Contact:Senthil Sundaram, Chief Financial
OfficerBrian Luque, Sr. Manager, Investor
Relationsinvestors@nightstartx.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Apr 2023 to Apr 2024